Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Micafungin

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Micafungin Sodium - Mycamine ® (opens in a new tab)Original source URL: https://globalrph.com/dilution/micafungin/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/micafungin/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:48:35.405834+00:00
Source location
div.post-content
Packaged content SHA-256
5ebde689277d1c09da404f2faa7894b6bd2a7360fd059990d86ac48cc89868cd
Original response SHA-256
404fc506f545eea648b5b1ce14a4764e40f78cf2f1e139b9accdb341e6f02c37
Source body SHA-256
b445933df979f2c67bc49db7d70566e0426503e0874055b18965c3a76b8320e5

Micafungin Sodium (Mycamine ®)

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS, D5W

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

[ 50 mg ] [ 100 ml] [ 1 hour]
[ 150 mg ] [100 ml] [1 hour]

Pediatric dilution info.

Reconstitution

Reconstitute micafungin for injection vials by aseptically adding 5 mL of one of the following compatible solutions:

  • 0.9% Sodium Chloride Injection, USP (without a bacteriostatic agent).
  • 5% Dextrose Injection, USP

To minimize excessive foaming, gently dissolve the micafungin for injection powder by swirling the vial.

Do not Vigorously Shake the Vial. Visually inspect the vial for particulate matter.

Micafungin for injection 50 mg vial: after reconstitution each mL contains 10 mg of micafungin

Micafungin for injection 100 mg vial: after reconstitution each mL contains 20 mg of micafungin

Stability*: 24 hours room temperature.

MYCAMINE® is a registered trademark of Astellas Pharma Inc. Note: Astellas Pharma US, Inc. lists the stability as 24 hours; however, a packager of this product - Par Pharmaceutical, Inc. lists the stability as 12 hours in their recent package insert with a revision date of 6/2021. Par Pharmaceutical revision (pdf).
*Translation: the manufacturer is likely moving to a shorter stability time (12 hours) which is reflected in the most recently revised monograph from Par Pharmaceuticals.

Label: Protect from light.

Description:

Micafungin for injection is a sterile, white lyophilized product for intravenous (IV) infusion that contains micafungin sodium. Micafungin sodium is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of Coleophoma empetri F-11899. Micafungin inhibits the synthesis of 1, 3-beta-D-glucan, an integral component of the fungal cell wall.

Each single-dose vial contains 50 mg micafungin (equivalent to 50.86 mg micafungin sodium) or 100 mg micafungin (equivalent to 101.73 mg micafungin sodium), 200 mg Lactose monohydrate, with Citric acid anhydrous and/or Sodium hydroxide (used for pH adjustment). Micafungin for injection must be diluted with 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP [see Dosage and Administration (2)]. Following reconstitution with 0.9% Sodium Chloride Injection, USP, the resulting pH of the solution is between 5 to 7.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

Micafungin is a member of the echinocandin class of antifungal agents

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:

Micafungin for injection is indicated for:

  • Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older.
  • Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age
  • Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older.
  • Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation.

Limitations of Use

  • The safety and effectiveness of micafungin for injection has not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed.
  • Micafungin for injection has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida.
  • The efficacy of micafungin for injection against infections caused by fungi other than Candida has not been established.

CONTRAINDICATIONS Return to article top

Contraindications:

Micafungin for injection is contraindicated in persons with known hypersensitivity to micafungin, any component of micafungin for injection, or other echinocandins.

WARNINGS AND PRECAUTIONS:
5.1 Hypersensitivity Reactions

Isolated cases of serious hypersensitivity (anaphylaxis and anaphylactoid) reactions (including shock) have been reported in patients receiving micafungin for injection. If these reactions occur, micafungin for injection infusion should be discontinued and appropriate treatment administered.

5.2 Hematological Effects

Acute intravascular hemolysis and hemoglobinuria was seen in a healthy volunteer during infusion of micafungin for injection (200 mg) and oral prednisolone (20 mg). Cases of significant hemolysis and hemolytic anemia have also been reported in patients treated with micafungin for injection. Patients who develop clinical or laboratory evidence of hemolysis or hemolytic anemia during micafungin for injection therapy should be monitored closely for evidence of worsening of these conditions and evaluated for the risk/benefit of continuing micafungin for injection therapy.

5.3 Hepatic Effects

Laboratory abnormalities in liver function tests have been seen in healthy volunteers and patients treated with micafungin for injection. In some patients with serious underlying conditions who were receiving micafungin for injection along with multiple concomitant medications, clinical hepatic abnormalities have occurred, and isolated cases of significant hepatic impairment, hepatitis, and hepatic failure have been reported. Patients who develop abnormal liver function tests during micafungin for injection therapy should be monitored for evidence of worsening hepatic function and evaluated for the risk/benefit of continuing micafungin for injection therapy.

5.4 Renal EffectsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)

Elevations in BUN and creatinine, and isolated cases of significant renal impairment or acute renal failure have been reported in patients who received micafungin for injection. In fluconazole-controlled trials, the incidence of drug-related renal adverse reactions was 0.4% for micafungin for injection treated patients and 0.5% for fluconazole treated patients. Patients who develop abnormal renal function tests during micafungin for injection therapy should be monitored for evidence of worsening renal function.

5.5 Infusion and Injection Site Reactions

Possible histamine-mediated symptoms have been reported with micafungin for injection, including rash, pruritus, facial swelling, and vasodilatation. Slow the infusion rate if infusion reaction occurs [see Dosage and Administration (2.3)].

Injection site reactions, including phlebitis and thrombophlebitis have been reported, at micafungin for injection doses of 50 to 150 mg/day. These reactions tended to occur more often in patients receiving micafungin for injection via peripheral intravenous administration [see Dosage and Administration (2.3) and Adverse Reactions (6.1)].

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:
  • Most common adverse reactions across adult and pediatric clinical trials for all indications include diarrhea, nausea, vomiting, abdominal pain, pyrexia, thrombocytopenia, neutropenia and headache (6.1)
  • In pediatric patients younger than 4 months of age, the following additional common adverse reactions were reported at an incidence rate of ≥15%: sepsis, acidosis, anemia, oxygen saturation decreased and hypokalemia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact: Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. Drug information

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
2.1 Dosage for Adults

The recommended dosage for adult patients based on indications are shown in Table 1.

Table 1. Micafungin for injection Dosage in Adult Patients
Indication Recommended Reconstituted Dose Once Daily
Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses* 100 mg
Treatment of Esophageal Candidiasis† 150 mg
Prophylaxis of Candida Infections in HSCT Recipients‡ 50 mg

* In patients treated successfully for candidemia and other Candida infections, the mean duration of treatment was 15 days (range 10 to 47 days).

† In patients treated successfully for esophageal candidiasis, the mean duration of treatment was 15 days (range 10 to 30 days).

‡ In hematopoietic stem cell transplant (HSCT) recipients who experienced success of prophylactic therapy, the mean duration of prophylaxis was 19 days (range 6 to 51 days).

2.2 Dosage for Pediatric Patients 4 Months and Older

The recommended dosage for pediatric patients 4 months of age and older based on indication and weight are shown in Table 2.

Table 2. Micafungin for injection Dosage in Pediatric Patients (4 Months of Age and Older)
Indication Dosage for Pediatric Patients 4 Months of Age and Older
30 kg or less Greater than 30 kg
Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses 2 mg/kg once daily (maximum daily dose 100 mg)
Treatment of Esophageal Candidiasis 3 mg/kg once daily 2.5 mg/kg once daily (maximum daily dose 150 mg)
Prophylaxis of Candida Infections in HSCT Recipients 1 mg/kg once daily (maximum daily dose 50 mg)
2.3 Dosage for Pediatric Patients Younger than 4 Months of Age

Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination

The recommended dosage is 4 mg/kg once daily.

The safety and effectiveness of micafungin for injection has not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [see Use in Specific Populations (8.4), Clinical Pharmacology (12.3) and Microbiology (12.4)].

2.4 Directions for Reconstitution, Dilution, and Preparation

Do not mix or co-infuse micafungin for injection with other medications. Micafungin for injection has been shown to precipitate when mixed directly with a number of other commonly used medications. Please read this entire section carefully before beginning reconstitution.

Reconstitution

Reconstitute micafungin for injection vials by aseptically adding 5 mL of one of the following compatible solutions:

  • 0.9% Sodium Chloride Injection, USP (without a bacteriostatic agent).
  • 5% Dextrose Injection, USP

To minimize excessive foaming, gently dissolve the micafungin for injection powder by swirling the vial.

Do not Vigorously Shake the Vial. Visually inspect the vial for particulate matter.

Micafungin for injection 50 mg vial: after reconstitution each mL contains 10 mg of micafungin

Micafungin for injection 100 mg vial: after reconstitution each mL contains 20 mg of micafungin

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if there is any evidence of precipitation or foreign matter. Aseptic technique must be strictly observed in all handling since no preservative or bacteriostatic agent is present in micafungin for injection or in the materials specified for reconstitution and dilution.

The reconstituted product should be protected from light and may be stored in the original vial for up to 24 hours at room temperature, 25°C (77°F).

Dilution and Preparation

The diluted solution should be protected from light. It is not necessary to cover the infusion drip chamber or the tubing.

Adult Patients:

1. Add the appropriate volume of reconstituted micafungin for injection into 100 mL of 0.9% Sodium Chloride Injection, USP or 100 mL of 5% Dextrose Injection, USP.

2. Appropriately label the bag.

--------------------------

Pediatric Patients:

1. Calculate the total micafungin for injection dose in milligrams (mg) by multiplying the recommended pediatric dose (mg/kg) for a given indication [see TABLE 2] and the weight of the patient in kilograms (kg).

2. To calculate the volume (mL) of drug needed, divide the calculated dose (mg) from step 1 by the final concentration of the selected reconstituted vial(s) (either 10 mg/mL for the 50 mg vial or 20 mg/mL for the 100 mg vial), see example below:

Using 50 mg vials:

Divide the calculated mg dose (from step 1) by 10 mg/mL to determine the volume (mL) needed.

OR

Using 100 mg vials:

Divide the calculated mg dose (from step 1) by 20 mg/mL to determine the volume (mL) needed.

3. Withdraw the calculated volume (mL) of drug needed from the selected concentration and size of reconstituted micafungin for injection vial(s) used in Step 2 (ensure the selected concentration and vial size used to calculate the dose is also used to prepare the infusion).

4. Add the withdrawn volume of drug (step 3) to a 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP intravenous infusion bag or syringe. Ensure that the final concentration of the solution is between 0.5 mg/mL to 4 mg/mL.

To decrease the risk of infusion reactions, concentrations above 1.5 mg/mL should be administered via central catheter [see Warnings and Precautions (5.5)].

5. Appropriately label the infusion bag or syringe. For concentrations above 1.5 mg/mL, if required, label to specifically warn to administer the solution via central catheter.

The diluted infusion bag should be protected from light and may be stored for up to 24 hours at room temperature, 25°C (77°F)

Micafungin for injection is preservative-free. Discard partially used vials.

2.5 Infusion Volume and Duration

Administer micafungin for injection by intravenous infusion only. Infuse over one hour. More rapid infusions may result in more frequent histamine-mediated reactions [see Warnings and Precautions (5.5)].

Flush an existing intravenous line with 0.9% Sodium Chloride Injection, USP, prior to infusion of micafungin for injection

Pediatric Patients

Micafungin for injection should be infused over one hour. To decrease the risk of infusion reactions, concentrations above 1.5 mg/mL should be administered via central catheter [see Warnings and Precautions (5.5)].

DOSAGE FORMS AND STRENGTHS:

Micafungin for injection is a sterile, white lyophilized powder for reconstitution for intravenous infusion available as:

  • 50 mg single-dose vial
  • 100 mg single-dose vial

Storage and Stability Return to article top

Micafungin for injection is supplied as a sterile, white lyophilized powder for reconstitution for intravenous infusion, and is available in the following packaging configurations:

• cartons of 10 individually packaged 50 mg single-dose vials, coated with a light protective film and sealed with a royal blue flip-off button. (NDC 60505-6119-5).
•cartons of 10 individually packaged 100 mg single-dose vials, coated with a light protective film and sealed with a red flip-off button. (NDC 60505-6120-6).

Storage

Unopened vials of lyophilized material must be stored at room temperature, Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].

Store the reconstituted product at 25°C (77°F). [see Dosage and Administration (2.4)]

Store the diluted solution at 25°C (77°F). [see Dosage and Administration (2.4)]

Protect from light

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
no_routine_adjustment_identified
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        class_level
        Provenance classification
        historical_class_level
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      micafungin
      Source IDH51-8B1E6BECF3100F969713198A
      Generic name
      Micafungin
      Source IDH51-7B79A8B4788EE575449DDFCB
      Class
      Antifungal
      Source IDH51-DE801D785BFC15C65EDCCE97
      Subclass
      Echinocandin
      Source IDH51-94AC3A7155B80EAAFD1988AE
      Primary uses
      1. Candidemia and invasive candidiasis
        Source IDH51-447DE609D3253B051A6A16B1
      2. Esophageal candidiasis
        Source IDH51-1FC783CE2E97220D2301EAF1
      3. Candida prophylaxis in selected transplant patients
        Source IDH51-800E262A6597622E8D10112B
      Mechanism
      Echinocandin inhibition of beta-(1,3)-D-glucan synthase reduces an essential fungal cell-wall component.
      Source IDH51-2D41AD6F979DB571DCF393EF
      Mechanism level
      class_level
      Source IDH51-347DFA0629FA250107E6D95A
      Basic dosing orientation
      Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 50 to 150 mg by indication | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose; indication and age dependent | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion
      Source IDH51-15558B3410950CE7B2C1EFC1
      Administration orientation
      Infuse over 1 hour
      Source IDH51-DCD9F9F006A121FD69BCEAC1
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context.
      Source IDH51-8BFDDE84583EA87F30702E96
      Key safety orientation
      1. Hypersensitivity, hemolysis, and hepatic adverse reactions.
        Source IDH51-AD95306E597CA9523073C608
      2. Rapid infusion may increase histamine-mediated reactions.
        Source IDH51-F2B65B23395ABBFB74288134
      Coverage path
      structured_local_snapshot
      Source IDH51-C4BA1A600DED5BA5D712FA35
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-57E60148F3530DF6C7E04D0F
      Legacy title
      Micafungin
      Source IDH51-82D8ED74BD49A6816B34E7CC
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-15F0D62AB176F27A1F393253
      Search text
      Micafungin Antifungal Echinocandin Candidemia and invasive candidiasis Esophageal candidiasis Candida prophylaxis in selected transplant patients Echinocandin inhibition of beta-(1,3)-D-glucan synthase reduces an essential fungal cell-wall component. Adult | Existing preparation record; use current package insert for indication-specific selection | Common dose 50 to 150 mg by indication | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric and neonatal | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose; indication and age dependent | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion Infuse over 1 hour No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context. Hypersensitivity, hemolysis, and hepatic adverse reactions. Rapid infusion may increase histamine-mediated reactions. Structured GlobalRPh route snapshot
      Source IDH51-BD0489F612BD9559D914D9AD
      Official access mode
      search
      Source IDH51-DBDD172C6F559D3F7AD5F4F1
      Official search query
      Micafungin
      Source IDH51-5C399A7C987C6FCEB6F9AB25
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-C889651655961EB3A70DD1BB

      No separate structured rows were bundled for IV push, continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical dilution and intermittent infusion preparation

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationAmountReconstitutionDiluentFinal volumeConcentrationRateStabilityNotes
      Source IDH51-08DEBF6C92EED56E448A5C57
      Adult
      Source IDH51-05A7B97D4DB812C5BE5363F0
      		Common dose 50 to 150 mg by indication
      Source IDH51-D8FB2B01AC0DA613B3FE07C4
      		Slowly add 5 mL NS or D5W to vial; gently swirl and minimize foaming.
      Source IDH51-51F23652CA1738AFF6A87BA0
      		NS or D5W
      Source IDH51-6395A00E999865C3C13294E2
      		100 mL
      Source IDH51-56C58A5AEA15A1FB87C036DA
      		Commonly 0.5 to 1.5 mg/mL
      Source IDH51-6CFAF288CB4F4DF4552CFCCB
      		Infuse over 1 hour
      Source IDH51-1CFB0DB65B7512CB311B20A8
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-4C181808169A4EDA6CED810E
      		Do not mix with other medications; protect bag as current label directs.
      Source IDH51-C896AD3BCF5B19789B2A0685
      Source IDH51-23592002021D3BC3DDCF6D63
      Pediatric and neonatal
      Source IDH51-B9BB9B18CD78F6248E045A87
      		Weight-based dose; indication and age dependent
      Source IDH51-7FC67C278BAACD0ECCE9738B
      		Reconstitute gently.
      Source IDH51-EAB63B44ED597CFCB6565EF7
      		NS or D5W
      Source IDH51-9479A44508CD1AFD9008BF47
      		Weight-appropriate volume
      Source IDH51-48EF65D02CB5BBB8E40DC949
      		Label-specified
      Source IDH51-0C6B0DD5339DA22F743CE4AA
      		Infuse over 1 hour
      Source IDH51-83227DEAC917BEDFF73BDEDB
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-345F95B78845C0CE2F2CFC0D

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-DBBAB3369C8859130535B937
      IV infusion
      Source IDH51-184B22B7053EA3C73BEB7499
      		Adult
      Source IDH51-61CD133F39DD79EE2BC02FCC
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-3AA9AA059F1AC26DD00E1978
      		Common dose 50 to 150 mg by indication
      Source IDH51-706BAA2812BF395B20E8D3A8
      		Not normalized in the preparation record
      Source IDH51-4692C9091C1E5AEBF50A74AF
      		See current package insert and professional guidance
      Source IDH51-FDD88DB04CA90FBAE995BCAD
      		Infuse over 1 hour
      Source IDH51-C0E5523A4BBF4187F294EEE4
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-612A35D097FE12A699D5879B
      		Do not mix with other medications; protect bag as current label directs.
      Source IDH51-F8D764E75F54B3A9C2C0F0DE
      Source IDH51-FF13D310213030181A2867E5
      IV infusion
      Source IDH51-12B678166F5AB62A6C5EAE29
      		Pediatric and neonatal
      Source IDH51-ED403F49ADFFEB98320F056B
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-FF9028F99DAFE5940819BFA4
      		Weight-based dose; indication and age dependent
      Source IDH51-BD1D13DCDBDF6B81684C4C69
      		Not normalized in the preparation record
      Source IDH51-FC2AF3D8164CDB73CDEFCB12
      		See current package insert and professional guidance
      Source IDH51-B700EAE56C8E342A84FE34D6
      		Infuse over 1 hour
      Source IDH51-B557210DC6A52D3716BA7F39
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-8BAD9972EC9F2D3DBB8734B5

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      no_routine_adjustment_identified
      Source IDH51-E9A7D291F6FE0D4B343CF28D
      Summary
      No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context.
      Source IDH51-473FC0A2C0F92780FD285639
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-D0614FAE46E0214B2E5AB0BA

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Candidemia and invasive candidiasis
        Source IDH51-332BB33E028157CF23C750D0
      2. Esophageal candidiasis
        Source IDH51-86C0154CBE1FA53BCF6370DB
      3. Candida prophylaxis in selected transplant patients
        Source IDH51-6C0F4ED736433925A10D6698

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Hypersensitivity, hemolysis, and hepatic adverse reactions.
        Source IDH51-703D90A1EF4171A2DBABD04E
      2. Rapid infusion may increase histamine-mediated reactions.
        Source IDH51-675EF1735E5758F814B90318

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      1. Hepatic tests
        Source IDH51-400100FF73BD6E16D289265E
      2. CBC when prolonged
        Source IDH51-ACF833C75E1E0EC6D23F388C
      3. Infusion reaction
        Source IDH51-9CE00CDC39281F12C17D7E64

      Historical supplemental professional sources

      Recovered v5.1 source content; historical, awaiting current review.

      LabelUrlKind
      Source IDH51-D9E031970F6EE585CC15E76B
      UCSF adult antimicrobial dosing, non-dialysis
      Source IDH51-041020B84B331F6AB2FEF838
      		https://idmp.ucsf.edu/adult-antimicrobial-dosing-non-dialysis (opens in a new tab)
      Source IDH51-4FBD62EADADAE46EFEBD3B41
      		Professional institutional guidance
      Source IDH51-B604EE878201A9978B0B0A32
      Source IDH51-AC502A3D3F8CA646D9EDEFB1
      UCSF antimicrobial dosing in intermittent and continuous hemodialysis
      Source IDH51-089EC58F1E49D2C2148FE20A
      		https://idmp.ucsf.edu/antimicrobial-dosing-intermittent-continuous-hemodialysis (opens in a new tab)
      Source IDH51-399B2DE98654A620C62EC049
      		Professional institutional guidance
      Source IDH51-BE4F5FF2DACAA3BB2907D676
      Source IDH51-FCCF97A8A087929843758444
      UCSF pediatric antimicrobial dosing
      Source IDH51-8C48BA05EB1889D1B687BB8E
      		https://idmp.ucsf.edu/pediatric-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-E81641FD9D92EA12B70B429E
      		Professional institutional guidance
      Source IDH51-79FD982435E774D8FC31E80B
      Source IDH51-E421E0FCE52FE33E74330EA6
      UCSF neonatal antimicrobial dosing
      Source IDH51-CF13275FB926117235EF7A31
      		https://idmp.ucsf.edu/neonatal-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-4087EC0717DB5FF2929BF45E
      		Professional institutional guidance
      Source IDH51-7B854D20D6013EDEDE637F74
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      micafungin
      Source IDH51-5A11F3A2C168EFDD55D3DCF6
      Generic name
      Micafungin
      Source IDH51-1ECC2FA9EC6DD57C160B4817
      Brand names
      1. Mycamine
        Source IDH51-02F372A952B5F10D97E50F4E
      Class
      Antifungal
      Source IDH51-E700C1505832A20E31261211
      Subclass
      Echinocandin
      Source IDH51-369E9427ABD1B9F6B33A1EED
      Summary
      Echinocandin requiring gentle reconstitution, further dilution, and one-hour infusion; protect prepared solution from light as labeled.
      Source IDH51-D6448CA6723A27E5F6E19A7B
      Populations
      1. Adult
        Source IDH51-9BB96E59C8D2B366502AD7FB
      2. Pediatric
        Source IDH51-4FCC31DDF8BEAF40D0C51B39
      3. Neonatal per current label
        Source IDH51-A45FB29A7BAA4C08439718FA
      Evidence tier
      Core reference - verify current label
      Source IDH51-BA10472EDD5BDAA5BDAFBA5C
      High alert
      false
      Source IDH51-40CE44FA72C53DF35E59C4CE
      Hazardous
      false
      Source IDH51-2BC182742A5BBC95C1A4A702
      Status
      Active
      Source IDH51-0B26D6B25C7329DEE4C281BD
      Reviewed
      2026-08-29
      Source IDH51-531A7FA852BC4DE15A41A5B4
      Version added
      1.2
      Source IDH51-794D8FACC0CDA62A2F2FDDB2
      Sources
      LabelUrlKind
      Source IDH51-1E95E7E628DDBD3335B47717
      DailyMed label search
      Source IDH51-B059BA2D7C02E41322B0F639
      		https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Micafungin (opens in a new tab)
      Source IDH51-EA1C2F7D5D4ACF4527AFA665
      		Primary
      Source IDH51-C40C13508ED6B16573094270
      Source IDH51-E3D0AC53F34517E4B5B2D76F
      GlobalRPh legacy IV dilution monograph
      Source IDH51-8351D492B7C81EF2C193067C
      		legacy:auto
      Source IDH51-CAB3372D6E9611A573AEF656
      		Legacy
      Source IDH51-04927112E30D8AEA7546DFAA
      Legacy title
      Micafungin
      Source IDH51-08A6D810B3218F003A836C09
      Clinical release verification
      Audit version
      3.4
      Source IDH51-3056992AF36003EBF15213F8
      Audited on
      2026-08-30
      Source IDH51-5BA2423DA3A427F58E92DC54
      Level
      amber
      Source IDH51-B2EEF56BF4FC6FE7E2C7D398
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-0AAF2979E8BB07E9E7DEB4EB
      Exact current label candidate
      false
      Source IDH51-F09259D0FCE33CB131407A22
      Numeric support ratio
      0
      Source IDH51-2EEA56FC0C4B54525D076EDC
      Reference url count
      5
      Source IDH51-87C350C05ECE1FD9234E0AFB
      Broken reference count
      0
      Source IDH51-C8354389A3E406283A2386A1
      Point of use confirmation required
      true
      Source IDH51-DDF51D2A8C8AFD942FB3433C
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-AEF7489C2FBE44F7FF2B9739

      Dosing source fields

      Id
      micafungin
      Source IDH51-9B08B47206166D29A35EED99
      Generic name
      Micafungin
      Source IDH51-D6EBA66655AD1199EF11FAB8
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-65C0DE30A1064941F9279F7D
      Package insert
      Query name
      Micafungin
      Source IDH51-0462B96D6881639D9F5EFC2A
      Product and route must match
      true
      Source IDH51-C46C1C2B5592A6CEAC9FB0E7
      Live current label enabled
      false
      Source IDH51-EA8A2E963C0E23EA1E0F288A
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-8F3F68C1911E6930B96113D8
      Direct official label access enabled
      true
      Source IDH51-9EA377A2E50C44ADE5671211
      Outbound server request required
      false
      Source IDH51-5EA3A17CD373D7F3AC5DF6BF
      Local summary status
      not_bundled
      Source IDH51-0D58C682FF096EC991C43C6D
      Clinical review
      Locally normalized
      false
      Source IDH51-08EF04C77A21C8CF2484040C
      Reviewed
      2026-08-29
      Source IDH51-04440121EF3C7F400DF435E6
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-18E5BC0332505361991A9773
      Clinical release verification
      Audit version
      3.4
      Source IDH51-87BCA0ED7740267562D928C3
      Audited on
      2026-08-30
      Source IDH51-DB02CD60D765C875AC170A03
      Level
      amber
      Source IDH51-CF7B7DA50F8DAF48275B0848
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-9095BA396635B7A00B51781F
      Exact current label candidate
      false
      Source IDH51-AB97AE6A76CF208E132B9FBE
      Numeric support ratio
      0
      Source IDH51-408FEE9924F57DCA5AE6FFF8
      Reference url count
      5
      Source IDH51-C4FD1EF9F4DCF8452DA8B0CE
      Broken reference count
      0
      Source IDH51-79CA524C2BA0E2E820FEC301
      Point of use confirmation required
      true
      Source IDH51-1BEDB53FB3E10ABA8E4F97AD
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-F0B238B00C304346DEE89238
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      micafungin
      Source IDH51-031E57BEF99FABF855BC9326
      Name
      Micafungin
      Source IDH51-928A2EA3B13BD1ECE6812498
      Brands
      Mycamine
      Source IDH51-11B095CDFBD3A15227860227
      Therapeutic class
      Antifungal
      Source IDH51-430AC27A40003F2E6DD509D7
      Review version
      3.1
      Source IDH51-5FC3B859A2246BC2E8951611
      Review date
      2026-08-30
      Source IDH51-F7D908D3F523D1D99AECCD29
      Release status
      structured_record_current_label_not_confirmed
      Source IDH51-CF228B8765993C8E68985819
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-704FC12CC433E41C4355D866
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-18FD6402DD5E824A1574A76E
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1DE051FB42A849D50E301FF3
      Reconstitution concentration
      Slowly add 5 mL NS or D5W to vial; gently swirl and minimize foaming. Reconstitute gently.
      Source IDH51-2E1338755925080C33FF65DD
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-C5F2B71753A29950AF935BC5
      Appropriate standardized containers
      100 mL Weight-appropriate volume
      Source IDH51-5A76C6E46CCA4B0C00CB0904
      Adult dosing range
      Common dose 50 to 150 mg by indication Weight-based dose; indication and age dependent
      Source IDH51-1230777AB6EADFC5F37F1450
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-3945849CC4631F381C16F4E0
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-38DA9238D7E5F59D30DFE1D9
      Infusion time
      Infuse over 1 hour
      Source IDH51-A6EF6883A7C7B11500FDC3C2
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-14EEFFA34ED1E64FF9D00CB3
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-B42375CE2C3925EA1409C17B
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-B5C14DB55C12D111B1A3EC6B
      Reconstitution concentration
      Primary
      existing_structured_record
      Source IDH51-E24E644C3357C4E521538EB1
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-CA10C8BFAEBCE7921A0A9C6C
      Appropriate standardized containers
      Primary
      existing_structured_record
      Source IDH51-AD2907EC9D33892901BB0E06
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-2D7D65F3CC1CF3E5F60897E7
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-C5D3EEAE848C709383CC96D3
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-EE13DC4AE6FBF5A081D3D5D4
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-079549C18852B0B34C186D5B
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-EA3166759D8C28A6AE2B7026
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-A754158C8514EBFDDDD29C2A
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-D698A043ACBA0BE5C9C16642
      Guide generation allowed
      true
      Source IDH51-97FC6EBDA18983268A5D7BDB
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-224F20DEA4ED84AEFDDE21C9
      Guide generation allowed
      false
      Source IDH51-99601627B7D3D7417FEB0FB1
      Neonatal
      Applicability
      supported_or_source_present
      Source IDH51-17C5160D2461CC281A1CC6ED
      Guide generation allowed
      false
      Source IDH51-1939FD6361C343E0915FAA3D
      Route presence
      Structured dilution
      true
      Source IDH51-460A946B8B22960ED3B426E7
      Iv push
      false
      Source IDH51-14CDE6DCB0618C2796FBCBAF
      Continuous infusion
      false
      Source IDH51-4FC03BB6E16700E016B3458A
      Pediatric source
      true
      Source IDH51-EE50FC7BAAEF15BA85E8D483
      Neonatal source
      true
      Source IDH51-47B404821702DB67CAC52651
      Legacy reference
      Status
      not_available
      Source IDH51-F60996C6CAC5496FAE89C769
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-98C3E75000E3F8FC1F1394D3
      Source files
      1. catalog.json
        Source IDH51-A33F2E424EA30A781E3B1240
      2. dosing.json
        Source IDH51-8BDFB9E57938F505117390CB
      3. legacy-map.json
        Source IDH51-738A85FD59BFA4BDD0056461
      4. new-in-v1.2.json
        Source IDH51-59A20B2FD17BC492D6DFCCCC
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-B5588C740D28E0161FE4933B
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-5A11F3A2C168EFDD55D3DCF6catalog.json
      /records/166/id      		Historical; current review incomplete
      H51-1ECC2FA9EC6DD57C160B4817catalog.json
      /records/166/generic_name      		Historical; current review incomplete
      H51-02F372A952B5F10D97E50F4Ecatalog.json
      /records/166/brand_names/0      		Historical; current review incomplete
      H51-E700C1505832A20E31261211catalog.json
      /records/166/class      		Historical; current review incomplete
      H51-369E9427ABD1B9F6B33A1EEDcatalog.json
      /records/166/subclass      		Historical; current review incomplete
      H51-D6448CA6723A27E5F6E19A7Bcatalog.json
      /records/166/summary      		Historical; current review incomplete
      H51-332BB33E028157CF23C750D0catalog.json
      /records/166/common_uses/0      		Historical; current review incomplete
      H51-86C0154CBE1FA53BCF6370DBcatalog.json
      /records/166/common_uses/1      		Historical; current review incomplete
      H51-6C0F4ED736433925A10D6698catalog.json
      /records/166/common_uses/2      		Historical; current review incomplete
      H51-08DEBF6C92EED56E448A5C57catalog.json
      /records/166/preparations/0      		Historical; current review incomplete
      H51-05A7B97D4DB812C5BE5363F0catalog.json
      /records/166/preparations/0/population      		Historical; current review incomplete
      H51-D8FB2B01AC0DA613B3FE07C4catalog.json
      /records/166/preparations/0/amount      		Historical; current review incomplete
      H51-51F23652CA1738AFF6A87BA0catalog.json
      /records/166/preparations/0/reconstitution      		Historical; current review incomplete
      H51-6395A00E999865C3C13294E2catalog.json
      /records/166/preparations/0/diluent      		Historical; current review incomplete
      H51-56C58A5AEA15A1FB87C036DAcatalog.json
      /records/166/preparations/0/final_volume      		Historical; current review incomplete
      H51-6CFAF288CB4F4DF4552CFCCBcatalog.json
      /records/166/preparations/0/concentration      		Historical; current review incomplete
      H51-1CFB0DB65B7512CB311B20A8catalog.json
      /records/166/preparations/0/rate      		Historical; current review incomplete
      H51-4C181808169A4EDA6CED810Ecatalog.json
      /records/166/preparations/0/stability      		Historical; current review incomplete
      H51-C896AD3BCF5B19789B2A0685catalog.json
      /records/166/preparations/0/notes      		Historical; current review incomplete
      H51-23592002021D3BC3DDCF6D63catalog.json
      /records/166/preparations/1      		Historical; current review incomplete
      H51-B9BB9B18CD78F6248E045A87catalog.json
      /records/166/preparations/1/population      		Historical; current review incomplete
      H51-7FC67C278BAACD0ECCE9738Bcatalog.json
      /records/166/preparations/1/amount      		Historical; current review incomplete
      H51-EAB63B44ED597CFCB6565EF7catalog.json
      /records/166/preparations/1/reconstitution      		Historical; current review incomplete
      H51-9479A44508CD1AFD9008BF47catalog.json
      /records/166/preparations/1/diluent      		Historical; current review incomplete
      H51-48EF65D02CB5BBB8E40DC949catalog.json
      /records/166/preparations/1/final_volume      		Historical; current review incomplete
      H51-0C6B0DD5339DA22F743CE4AAcatalog.json
      /records/166/preparations/1/concentration      		Historical; current review incomplete
      H51-83227DEAC917BEDFF73BDEDBcatalog.json
      /records/166/preparations/1/rate      		Historical; current review incomplete
      H51-345F95B78845C0CE2F2CFC0Dcatalog.json
      /records/166/preparations/1/stability      		Historical; current review incomplete
      H51-9FA8B9579C2DC5999125B6F2catalog.json
      /records/166/preparations/1/notes      		Historical; current review incomplete
      H51-703D90A1EF4171A2DBABD04Ecatalog.json
      /records/166/warnings/0      		Historical; current review incomplete
      H51-675EF1735E5758F814B90318catalog.json
      /records/166/warnings/1      		Historical; current review incomplete
      H51-400100FF73BD6E16D289265Ecatalog.json
      /records/166/monitoring/0      		Historical; current review incomplete
      H51-ACF833C75E1E0EC6D23F388Ccatalog.json
      /records/166/monitoring/1      		Historical; current review incomplete
      H51-9CE00CDC39281F12C17D7E64catalog.json
      /records/166/monitoring/2      		Historical; current review incomplete
      H51-9BB96E59C8D2B366502AD7FBcatalog.json
      /records/166/populations/0      		Historical; current review incomplete
      H51-4FCC31DDF8BEAF40D0C51B39catalog.json
      /records/166/populations/1      		Historical; current review incomplete
      H51-A45FB29A7BAA4C08439718FAcatalog.json
      /records/166/populations/2      		Historical; current review incomplete
      H51-BA10472EDD5BDAA5BDAFBA5Ccatalog.json
      /records/166/evidence_tier      		Historical; current review incomplete
      H51-40CE44FA72C53DF35E59C4CEcatalog.json
      /records/166/high_alert      		Historical; current review incomplete
      H51-2BC182742A5BBC95C1A4A702catalog.json
      /records/166/hazardous      		Historical; current review incomplete
      H51-0B26D6B25C7329DEE4C281BDcatalog.json
      /records/166/status      		Historical; current review incomplete
      H51-531A7FA852BC4DE15A41A5B4catalog.json
      /records/166/reviewed      		Historical; current review incomplete
      H51-794D8FACC0CDA62A2F2FDDB2catalog.json
      /records/166/version_added      		Historical; current review incomplete
      H51-1E95E7E628DDBD3335B47717catalog.json
      /records/166/sources/0      		Historical; current review incomplete
      H51-B059BA2D7C02E41322B0F639catalog.json
      /records/166/sources/0/label      		Historical; current review incomplete
      H51-EA1C2F7D5D4ACF4527AFA665catalog.json
      /records/166/sources/0/url      		Historical; current review incomplete
      H51-C40C13508ED6B16573094270catalog.json
      /records/166/sources/0/kind      		Historical; current review incomplete
      H51-E3D0AC53F34517E4B5B2D76Fcatalog.json
      /records/166/sources/1      		Historical; current review incomplete
      H51-8351D492B7C81EF2C193067Ccatalog.json
      /records/166/sources/1/label      		Historical; current review incomplete
      H51-CAB3372D6E9611A573AEF656catalog.json
      /records/166/sources/1/url      		Historical; current review incomplete
      H51-04927112E30D8AEA7546DFAAcatalog.json
      /records/166/sources/1/kind      		Historical; current review incomplete
      H51-08A6D810B3218F003A836C09catalog.json
      /records/166/legacy_title      		Historical; current review incomplete
      H51-3056992AF36003EBF15213F8catalog.json
      /records/166/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-5BA2423DA3A427F58E92DC54catalog.json
      /records/166/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-B2EEF56BF4FC6FE7E2C7D398catalog.json
      /records/166/clinical_release_verification/level      		Historical; current review incomplete
      H51-0AAF2979E8BB07E9E7DEB4EBcatalog.json
      /records/166/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-F09259D0FCE33CB131407A22catalog.json
      /records/166/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-E3A97883E9F945DA31423043catalog.json
      /records/166/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-F7DF575775309B2177BBFEEBcatalog.json
      /records/166/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-2EEA56FC0C4B54525D076EDCcatalog.json
      /records/166/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-87C350C05ECE1FD9234E0AFBcatalog.json
      /records/166/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-C8354389A3E406283A2386A1catalog.json
      /records/166/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-DDF51D2A8C8AFD942FB3433Ccatalog.json
      /records/166/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-AEF7489C2FBE44F7FF2B9739catalog.json
      /records/166/clinical_release_verification/note      		Historical; current review incomplete
      H51-C06B569937040B2B15B07B5Bcatalog.json
      /records/166/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-9B08B47206166D29A35EED99dosing.json
      /records/166/id      		Historical; current review incomplete
      H51-D6EBA66655AD1199EF11FAB8dosing.json
      /records/166/generic_name      		Historical; current review incomplete
      H51-65C0DE30A1064941F9279F7Ddosing.json
      /records/166/coverage_status      		Historical; current review incomplete
      H51-0462B96D6881639D9F5EFC2Adosing.json
      /records/166/package_insert/query_name      		Historical; current review incomplete
      H51-AA60A1F7B985D77922CEAA87dosing.json
      /records/166/package_insert/preferred_setid      		Historical; current review incomplete
      H51-C46C1C2B5592A6CEAC9FB0E7dosing.json
      /records/166/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-EA8A2E963C0E23EA1E0F288Adosing.json
      /records/166/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-8F3F68C1911E6930B96113D8dosing.json
      /records/166/package_insert/source_priority      		Historical; current review incomplete
      H51-9EA377A2E50C44ADE5671211dosing.json
      /records/166/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-5EA3A17CD373D7F3AC5DF6BFdosing.json
      /records/166/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-0D58C682FF096EC991C43C6Ddosing.json
      /records/166/package_insert/local_summary_status      		Historical; current review incomplete
      H51-E9A7D291F6FE0D4B343CF28Ddosing.json
      /records/166/renal/classification      		Historical; current review incomplete
      H51-473FC0A2C0F92780FD285639dosing.json
      /records/166/renal/summary      		Historical; current review incomplete
      H51-D0614FAE46E0214B2E5AB0BAdosing.json
      /records/166/renal/method_note      		Historical; current review incomplete
      H51-DBBAB3369C8859130535B937dosing.json
      /records/166/existing_route_snapshots/0      		Historical; current review incomplete
      H51-184B22B7053EA3C73BEB7499dosing.json
      /records/166/existing_route_snapshots/0/route      		Historical; current review incomplete
      H51-61CD133F39DD79EE2BC02FCCdosing.json
      /records/166/existing_route_snapshots/0/population      		Historical; current review incomplete
      H51-3AA9AA059F1AC26DD00E1978dosing.json
      /records/166/existing_route_snapshots/0/indication      		Historical; current review incomplete
      H51-706BAA2812BF395B20E8D3A8dosing.json
      /records/166/existing_route_snapshots/0/dose      		Historical; current review incomplete
      H51-4692C9091C1E5AEBF50A74AFdosing.json
      /records/166/existing_route_snapshots/0/interval      		Historical; current review incomplete
      H51-FDD88DB04CA90FBAE995BCADdosing.json
      /records/166/existing_route_snapshots/0/duration      		Historical; current review incomplete
      H51-C0E5523A4BBF4187F294EEE4dosing.json
      /records/166/existing_route_snapshots/0/administration      		Historical; current review incomplete
      H51-612A35D097FE12A699D5879Bdosing.json
      /records/166/existing_route_snapshots/0/source_level      		Historical; current review incomplete
      H51-F8D764E75F54B3A9C2C0F0DEdosing.json
      /records/166/existing_route_snapshots/0/notes      		Historical; current review incomplete
      H51-FF13D310213030181A2867E5dosing.json
      /records/166/existing_route_snapshots/1      		Historical; current review incomplete
      H51-12B678166F5AB62A6C5EAE29dosing.json
      /records/166/existing_route_snapshots/1/route      		Historical; current review incomplete
      H51-ED403F49ADFFEB98320F056Bdosing.json
      /records/166/existing_route_snapshots/1/population      		Historical; current review incomplete
      H51-FF9028F99DAFE5940819BFA4dosing.json
      /records/166/existing_route_snapshots/1/indication      		Historical; current review incomplete
      H51-BD1D13DCDBDF6B81684C4C69dosing.json
      /records/166/existing_route_snapshots/1/dose      		Historical; current review incomplete
      H51-FC2AF3D8164CDB73CDEFCB12dosing.json
      /records/166/existing_route_snapshots/1/interval      		Historical; current review incomplete
      H51-B700EAE56C8E342A84FE34D6dosing.json
      /records/166/existing_route_snapshots/1/duration      		Historical; current review incomplete
      H51-B557210DC6A52D3716BA7F39dosing.json
      /records/166/existing_route_snapshots/1/administration      		Historical; current review incomplete
      H51-8BAD9972EC9F2D3DBB8734B5dosing.json
      /records/166/existing_route_snapshots/1/source_level      		Historical; current review incomplete
      H51-8E3C5E7EFF4671355C57C440dosing.json
      /records/166/existing_route_snapshots/1/notes      		Historical; current review incomplete
      H51-D9E031970F6EE585CC15E76Bdosing.json
      /records/166/professional_sources/0      		Historical; current review incomplete
      H51-041020B84B331F6AB2FEF838dosing.json
      /records/166/professional_sources/0/label      		Historical; current review incomplete
      H51-4FBD62EADADAE46EFEBD3B41dosing.json
      /records/166/professional_sources/0/url      		Historical; current review incomplete
      H51-B604EE878201A9978B0B0A32dosing.json
      /records/166/professional_sources/0/kind      		Historical; current review incomplete
      H51-AC502A3D3F8CA646D9EDEFB1dosing.json
      /records/166/professional_sources/1      		Historical; current review incomplete
      H51-089EC58F1E49D2C2148FE20Adosing.json
      /records/166/professional_sources/1/label      		Historical; current review incomplete
      H51-399B2DE98654A620C62EC049dosing.json
      /records/166/professional_sources/1/url      		Historical; current review incomplete
      H51-BE4F5FF2DACAA3BB2907D676dosing.json
      /records/166/professional_sources/1/kind      		Historical; current review incomplete
      H51-FCCF97A8A087929843758444dosing.json
      /records/166/professional_sources/2      		Historical; current review incomplete
      H51-8C48BA05EB1889D1B687BB8Edosing.json
      /records/166/professional_sources/2/label      		Historical; current review incomplete
      H51-E81641FD9D92EA12B70B429Edosing.json
      /records/166/professional_sources/2/url      		Historical; current review incomplete
      H51-79FD982435E774D8FC31E80Bdosing.json
      /records/166/professional_sources/2/kind      		Historical; current review incomplete
      H51-E421E0FCE52FE33E74330EA6dosing.json
      /records/166/professional_sources/3      		Historical; current review incomplete
      H51-CF13275FB926117235EF7A31dosing.json
      /records/166/professional_sources/3/label      		Historical; current review incomplete
      H51-4087EC0717DB5FF2929BF45Edosing.json
      /records/166/professional_sources/3/url      		Historical; current review incomplete
      H51-7B854D20D6013EDEDE637F74dosing.json
      /records/166/professional_sources/3/kind      		Historical; current review incomplete
      H51-08EF04C77A21C8CF2484040Cdosing.json
      /records/166/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-04440121EF3C7F400DF435E6dosing.json
      /records/166/clinical_review/reviewed      		Historical; current review incomplete
      H51-18E5BC0332505361991A9773dosing.json
      /records/166/clinical_review/status      		Historical; current review incomplete
      H51-87BCA0ED7740267562D928C3dosing.json
      /records/166/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-DB02CD60D765C875AC170A03dosing.json
      /records/166/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-CF7B7DA50F8DAF48275B0848dosing.json
      /records/166/clinical_release_verification/level      		Historical; current review incomplete
      H51-9095BA396635B7A00B51781Fdosing.json
      /records/166/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-AB97AE6A76CF208E132B9FBEdosing.json
      /records/166/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-2246FE36446DF950B56F4707dosing.json
      /records/166/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-AD3CF121D2A0712CA5549967dosing.json
      /records/166/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-408FEE9924F57DCA5AE6FFF8dosing.json
      /records/166/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-C4FD1EF9F4DCF8452DA8B0CEdosing.json
      /records/166/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-79CA524C2BA0E2E820FEC301dosing.json
      /records/166/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-1BEDB53FB3E10ABA8E4F97ADdosing.json
      /records/166/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-F0B238B00C304346DEE89238dosing.json
      /records/166/clinical_release_verification/note      		Historical; current review incomplete
      H51-468058BD609589A2D8CE2DC9dosing.json
      /records/166/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-8B1E6BECF3100F969713198Afirst-look-v5.1.json
      /records/166/id      		Historical; current review incomplete
      H51-7B79A8B4788EE575449DDFCBfirst-look-v5.1.json
      /records/166/generic_name      		Historical; current review incomplete
      H51-DE801D785BFC15C65EDCCE97first-look-v5.1.json
      /records/166/class      		Historical; current review incomplete
      H51-94AC3A7155B80EAAFD1988AEfirst-look-v5.1.json
      /records/166/subclass      		Historical; current review incomplete
      H51-447DE609D3253B051A6A16B1first-look-v5.1.json
      /records/166/primary_uses/0      		Historical; current review incomplete
      H51-1FC783CE2E97220D2301EAF1first-look-v5.1.json
      /records/166/primary_uses/1      		Historical; current review incomplete
      H51-800E262A6597622E8D10112Bfirst-look-v5.1.json
      /records/166/primary_uses/2      		Historical; current review incomplete
      H51-2D41AD6F979DB571DCF393EFfirst-look-v5.1.json
      /records/166/mechanism      		Historical; current review incomplete
      H51-347DFA0629FA250107E6D95Afirst-look-v5.1.json
      /records/166/mechanism_level      		Historical; current review incomplete
      H51-15558B3410950CE7B2C1EFC1first-look-v5.1.json
      /records/166/basic_dosing_orientation      		Historical; current review incomplete
      H51-DCD9F9F006A121FD69BCEAC1first-look-v5.1.json
      /records/166/administration_orientation      		Historical; current review incomplete
      H51-8BFDDE84583EA87F30702E96first-look-v5.1.json
      /records/166/renal_and_population_orientation      		Historical; current review incomplete
      H51-AD95306E597CA9523073C608first-look-v5.1.json
      /records/166/key_safety_orientation/0      		Historical; current review incomplete
      H51-F2B65B23395ABBFB74288134first-look-v5.1.json
      /records/166/key_safety_orientation/1      		Historical; current review incomplete
      H51-C4BA1A600DED5BA5D712FA35first-look-v5.1.json
      /records/166/coverage_path      		Historical; current review incomplete
      H51-57E60148F3530DF6C7E04D0Ffirst-look-v5.1.json
      /records/166/coverage_path_label      		Historical; current review incomplete
      H51-F058A62613D437224335E054first-look-v5.1.json
      /records/166/official_label_url      		Historical; current review incomplete
      H51-82D8ED74BD49A6816B34E7CCfirst-look-v5.1.json
      /records/166/legacy_title      		Historical; current review incomplete
      H51-15F0D62AB176F27A1F393253first-look-v5.1.json
      /records/166/review_note      		Historical; current review incomplete
      H51-BD0489F612BD9559D914D9ADfirst-look-v5.1.json
      /records/166/search_text      		Historical; current review incomplete
      H51-348C68831F238061567E63F4first-look-v5.1.json
      /records/166/official_search_url      		Historical; current review incomplete
      H51-DBDD172C6F559D3F7AD5F4F1first-look-v5.1.json
      /records/166/official_access_mode      		Historical; current review incomplete
      H51-80A35AF9F3BB03E23660255Efirst-look-v5.1.json
      /records/166/official_access_url      		Historical; current review incomplete
      H51-5C399A7C987C6FCEB6F9AB25first-look-v5.1.json
      /records/166/official_search_query      		Historical; current review incomplete
      H51-C889651655961EB3A70DD1BBfirst-look-v5.1.json
      /records/166/official_access_reason      		Historical; current review incomplete
      H51-031E57BEF99FABF855BC9326preparation-assessments-v3.8.json
      /166/id      		Historical; current review incomplete
      H51-928A2EA3B13BD1ECE6812498preparation-assessments-v3.8.json
      /166/name      		Historical; current review incomplete
      H51-11B095CDFBD3A15227860227preparation-assessments-v3.8.json
      /166/brands      		Historical; current review incomplete
      H51-430AC27A40003F2E6DD509D7preparation-assessments-v3.8.json
      /166/therapeutic_class      		Historical; current review incomplete
      H51-5FC3B859A2246BC2E8951611preparation-assessments-v3.8.json
      /166/review_version      		Historical; current review incomplete
      H51-F7D908D3F523D1D99AECCD29preparation-assessments-v3.8.json
      /166/review_date      		Historical; current review incomplete
      H51-CF228B8765993C8E68985819preparation-assessments-v3.8.json
      /166/release_status      		Historical; current review incomplete
      H51-704FC12CC433E41C4355D866preparation-assessments-v3.8.json
      /166/market_status/status      		Historical; current review incomplete
      H51-18FD6402DD5E824A1574A76Epreparation-assessments-v3.8.json
      /166/market_status/basis      		Historical; current review incomplete
      H51-1DE051FB42A849D50E301FF3preparation-assessments-v3.8.json
      /166/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-2E1338755925080C33FF65DDpreparation-assessments-v3.8.json
      /166/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-C5F2B71753A29950AF935BC5preparation-assessments-v3.8.json
      /166/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-5A76C6E46CCA4B0C00CB0904preparation-assessments-v3.8.json
      /166/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-1230777AB6EADFC5F37F1450preparation-assessments-v3.8.json
      /166/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-3945849CC4631F381C16F4E0preparation-assessments-v3.8.json
      /166/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-38DA9238D7E5F59D30DFE1D9preparation-assessments-v3.8.json
      /166/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-A6EF6883A7C7B11500FDC3C2preparation-assessments-v3.8.json
      /166/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-14EEFFA34ED1E64FF9D00CB3preparation-assessments-v3.8.json
      /166/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-85BCE84566FB09439D0F3750preparation-assessments-v3.8.json
      /166/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-854EFEE64C3440E330525C9Cpreparation-assessments-v3.8.json
      /166/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-DBCA52AF7EB3AEB6FC471D84preparation-assessments-v3.8.json
      /166/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-7ECDC63B95E8AA8C663846FApreparation-assessments-v3.8.json
      /166/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-B42375CE2C3925EA1409C17Bpreparation-assessments-v3.8.json
      /166/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-FCACC85DF006B48A3699172Dpreparation-assessments-v3.8.json
      /166/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-B5C14DB55C12D111B1A3EC6Bpreparation-assessments-v3.8.json
      /166/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-E24E644C3357C4E521538EB1preparation-assessments-v3.8.json
      /166/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-CA10C8BFAEBCE7921A0A9C6Cpreparation-assessments-v3.8.json
      /166/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-AD2907EC9D33892901BB0E06preparation-assessments-v3.8.json
      /166/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-2D7D65F3CC1CF3E5F60897E7preparation-assessments-v3.8.json
      /166/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-C5D3EEAE848C709383CC96D3preparation-assessments-v3.8.json
      /166/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-EE13DC4AE6FBF5A081D3D5D4preparation-assessments-v3.8.json
      /166/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-079549C18852B0B34C186D5Bpreparation-assessments-v3.8.json
      /166/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-EA3166759D8C28A6AE2B7026preparation-assessments-v3.8.json
      /166/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-A754158C8514EBFDDDD29C2Apreparation-assessments-v3.8.json
      /166/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-D698A043ACBA0BE5C9C16642preparation-assessments-v3.8.json
      /166/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-97FC6EBDA18983268A5D7BDBpreparation-assessments-v3.8.json
      /166/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-224F20DEA4ED84AEFDDE21C9preparation-assessments-v3.8.json
      /166/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-99601627B7D3D7417FEB0FB1preparation-assessments-v3.8.json
      /166/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-17C5160D2461CC281A1CC6EDpreparation-assessments-v3.8.json
      /166/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-1939FD6361C343E0915FAA3Dpreparation-assessments-v3.8.json
      /166/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-460A946B8B22960ED3B426E7preparation-assessments-v3.8.json
      /166/route_presence/structured_dilution      		Historical; current review incomplete
      H51-14CDE6DCB0618C2796FBCBAFpreparation-assessments-v3.8.json
      /166/route_presence/iv_push      		Historical; current review incomplete
      H51-4FC03BB6E16700E016B3458Apreparation-assessments-v3.8.json
      /166/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-EE50FC7BAAEF15BA85E8D483preparation-assessments-v3.8.json
      /166/route_presence/pediatric_source      		Historical; current review incomplete
      H51-47B404821702DB67CAC52651preparation-assessments-v3.8.json
      /166/route_presence/neonatal_source      		Historical; current review incomplete
      H51-F60996C6CAC5496FAE89C769preparation-assessments-v3.8.json
      /166/legacy_reference/status      		Historical; current review incomplete
      H51-98C3E75000E3F8FC1F1394D3preparation-assessments-v3.8.json
      /166/label_resolution/status      		Historical; current review incomplete
      H51-A33F2E424EA30A781E3B1240preparation-assessments-v3.8.json
      /166/source_files/0      		Historical; current review incomplete
      H51-8BDFB9E57938F505117390CBpreparation-assessments-v3.8.json
      /166/source_files/1      		Historical; current review incomplete
      H51-738A85FD59BFA4BDD0056461preparation-assessments-v3.8.json
      /166/source_files/2      		Historical; current review incomplete
      H51-59A20B2FD17BC492D6DFCCCCpreparation-assessments-v3.8.json
      /166/source_files/3      		Historical; current review incomplete
      H51-B5588C740D28E0161FE4933Bpreparation-assessments-v3.8.json
      /166/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top